ArticleBMC pregnancy and childbirth2025
Elabela as a predictive biomarker for placenta accreta spectrum: a case-control study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prenatal ultrasound markers for predicting blood transfusion in placenta accreta spectrum.BMC pregnancy and childbirth · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate maternal serum Elabela (ELA) levels in pregnancies complicated by placenta accreta spectrum (PAS) and to assess their association with disease severity and predictive value for adverse obstetric outcomes. MATERIALS AND
methodsIn this prospective case-control study conducted at the Department of Perinatology, Ankara Etlik City Hospital (Türkiye) between February and July 2025, 88 pregnant women were included: 44 with PAS and 44 healthy controls matched for maternal age and gestational age. Maternal serum ELA levels were measured using a commercially available ELISA kit. Demographic, obstetric, clinical, and perinatal data were recorded. Receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic performance of ELA, and logistic regression was used to evaluate its predictive value for PAS.
resultsMedian ELA levels were significantly higher in the PAS group compared to controls (2600.38 [2419.52-2700.75] vs. 2359.65 [2249.25-2490.63] pg/mL; p < 0.001). The area under the ROC curve was 0.721 (p < 0.001; 95% CI: 0.615-0.811). The optimal cut-off value of 2488.75 pg/mL predicted PAS with 70.5% sensitivity, 75.0% specificity, a positive likelihood ratio of 2.82, and a negative likelihood ratio of 0.39.
conclusionElevated maternal serum ELA levels are associated with PAS and may serve as a potential biomarker for its prenatal identification. Further large-scale prospective studies are warranted to confirm its diagnostic utility and to explore its role in disease pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.